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Strategies targeting pathological angiogenesis have
focused primarily on blocking vascular endothelial
growth factor (VEGF), but resistance and insufficient
efficacy limit their success, mandating alternative
antiangiogenic strategies. We recently provided
genetic evidence that the glycolytic activator phos-
phofructokinase-2/fructose-2,6-bisphosphatase 3
(PFKFB3) promotes vessel formation but did not
explore the antiangiogenic therapeutic potential of
PFKFB3 blockade. Here, we show that blockade
of PFKFB3 by the small molecule 3-(3-pyridinyl)-1-
(4-pyridinyl)-2-propen-1-one (3PO) reduced vessel
sprouting in endothelial cell (EC) spheroids, zebra-
fish embryos, and the postnatal mouse retina by in-
hibiting EC proliferation and migration. 3PO also
suppressed vascular hyperbranching induced by in-
hibition of Notch or VEGF receptor 1 (VEGFR1) and
amplified the antiangiogenic effect of VEGF
blockade. Although 3PO reduced glycolysis only
partially and transiently in vivo, this sufficed to
decrease pathological neovascularization in ocular
and inflammatory models. These insights may offer
therapeutic antiangiogenic opportunities.
INTRODUCTION
Angiogenesis stimulates the progression of numerous disorders.
Hence, targeting this process by blocking angiogenic signals
such as vascular endothelial growth factor (VEGF) has becomeCa clinically attractive strategy (Singh and Ferrara, 2012). Howev-
er, insufficient efficacy and resistance limit its success (Ebos and
Kerbel, 2011; Potente et al., 2011). Although combination treat-
ment with multiple agents blocking distinct angiogenic signals
might offer benefit, a concern remains that angiogenesis re-
lapses through compensation by other angiogenic factors. We
therefore explored a fundamentally different antiangiogenic
strategy.
Targeting endothelial cell (EC) metabolism for antiangiogene-
sis has received little attention (De Bock et al., 2013a; Harjes
et al., 2012). Since angiogenic signaling pathways converge
onto metabolism, and ECs rely on glycolysis for generating
most (85%) of their ATP (De Bock et al., 2013b), we hypothesized
that targeting glycolysis might provide an alternative therapeutic
opportunity for reducing pathological neovascularization. How-
ever, given that previous antiglycolytic, anticancer therapies
were not always successful (Granchi and Minutolo, 2012; Raez
et al., 2013), it was unknown if antiglycolytic strategies could
inhibit pathological angiogenesis.
We focused on phosphofructokinase-2/fructose-2,6-bi-
sphosphatase-3 (PFKFB3), since silencing in vitro or inactiva-
tion in vivo of this glycolytic activator reduced glycolysis and
impaired vessel sprouting (De Bock et al., 2013b). This enzyme
is an activator of a key glycolytic enzyme, 6-phosphofructo-1-
kinase (PFK-1), which converts fructose-6-phosphate (F6P)
to fructose-1,6-bisphosphate (F1,6P2). PFKFB isoenzymes
synthesize fructose-2,6-bisphosphate (F2,6P2), an allosteric
activator of PFK-1 and potent stimulator of glycolysis (Van
Schaftingen et al., 1982). Of all PFKFB isoenzymes, PFKFB3
has a much (700-fold) higher kinase than bisphosphatase activ-
ity and promotes production of F2,6P2 and glycolysis (Yalcin
et al., 2009). PFKFB3 is also the most abundant isoenzyme in
ECs (De Bock et al., 2013b). Here, we characterized the antian-
giogenic therapeutic potential of a PFKFB3 inhibitor.ell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc. 37
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Figure 1. 3PO Inhibits Glycolysis in ECs
(A) Glycolytic flux in control or PFKFB3-silenced ECs, showing that 3PO reduced glycolysis in control cells but was ineffective in further reducing glycolysis in
PFKFB3-silenced cells (mean ± SEM; n = 3; *p < 0.05 versus vehicle; &p < 0.05 versus control).
(B) Quantification of fructose-2,6-bisphosphate (F2,6P2) content, showing reduced F2,6P2 levels after PFKFB3 inhibition by 3PO (mean ± SEM; n = 3; *p < 0.05).
(C) PFKFB3 blockade by 3PO did not affect the energy charge ([ATP] + ½[ADP]) / ([ATP] + [ADP] + [AMP]) (mean ± SEM; n = 3; p = not significant [NS]) at 24 hr.
(D) Enzymatic activity of glycolytic enzymesmeasured in extracts of ECs, treated with a concentration of 3PO or YN1 that effectively inhibited glycolysis, showing
that these PFKFB3 blockers failed to affect their enzymatic activity (mean ± SEM; n = 3; *p < 0.05). HK, hexokinase; G6PD, glucose 6-phosphate dehydrogenase;
TKT, transketolase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PK, pyruvate kinase; LDH, lactate dehydrogenase.
(E) Glucose uptake in vivo, showing that a first injection of 3PO (vertical arrow 1) lowered 2-[1-14C]-DG uptake in the diaphragm modestly and transiently during
the first 6 hr, but not after 24 hr. A second administration of 3PO after 24 hr (vertical arrow 2) reduced glucose uptake again to the same level as the first
administration (mean ± SEM; n = 3; *p < 0.05).
(F) GC-MS analysis of 13C enrichment in lactate, showing that lactate production from [U-13C]-glucose in the blood was transiently reduced upon 3PO treatment
after 1 hr, but not any longer after 24 hr (mean ± SEM; n = 4 for ctrl and n = 5 for 3PO; *p < 0.05 versus vehicle at the same time point).
(G) [6-14C]glucose incorporation assay, showing that 3PO reduced the synthesis of RNA in EC monolayers (mean ± SEM; n = 3; *p < 0.01).
(H) [3H]thymidine incorporation assay, showing that 3PO reduced proliferation of EC monolayers (mean ± SEM; n = 3; *p < 0.01).
(I) FACS quantification of 5-ethynyl-20-deoxyuridine (EdU) ECs, showing that 3PO treatment increased the fraction of quiescent ECs. Upon reseeding in the
absence of 3PO, ECs reinitiate proliferation (mean ± SEM; n = 3; *p < 0.05).
(J) Glycolytic flux is lower in quiescent ECs (81% ± 3% synchronized in G0/G1 by contact inhibition [CI]) than in proliferating (prol) ECs (35% ± 1% in G0 upon
replating) (mean ± SEM; n = 3; *p < 0.05).
(K) Quantification of MitoC-treated EC migration in scratch wound assays over time (10 and 24 hr), showing reduced migration upon PFKFB3 blockade (3PO).
When 3PO was removed from the medium 10 hr after the initiation of the treatment, ECs resumed migration (mean ± SEM; n = 3; *p < 0.05). See also Figure S1.
Cell Metabolism
PFKFB3 Blockade Reduces Pathological AngiogenesisRESULTS
PFKFB3 Blockers Reduce Glycolysis in EC Monolayers
In Vitro
To explore if pharmacological blockade of the kinase activity of
PFKFB3 reduced glycolysis in human umbilical venous endothe-
lial cells (HUVECs, abbreviated as ECs) and affected vessel
sprouting, we used the small molecule compound 3-(3-pyri-
dinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) (Chesney et al.,38 Cell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc.1999; Clem et al., 2008). Key findings were confirmed by us-
ing 7,8-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one (YN1),
another PFKFB3 blocker (Seo et al., 2011). 3PO and YN1 dose
dependently reduced glycolysis in ECs, but by no more than
35%–40% (Figure 1A; Figure S1A available online). 3PO evoked
comparable effects in arterial ECs (Figure S1B). PFKFB3
blockade thus reduced glycolysis incompletely, i.e., less than
the nonmetabolizable glucose analog 2-deoxy-D-glucose
(2DG), which reduced glycolysis by 80% (Figure S1C). 3PO
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PFKFB3 Blockade Reduces Pathological Angiogenesisalso lowered F2,6P2 levels by 41% (Figure 1B). 3PO, however,
did not lower the energy charge (Figure 1C) and, unlike 2DG,
did not increase oxygen consumption (Figure S1D).
3PO and YN1 did not inhibit the enzymatic activity of a panel of
glycolytic enzymes when analyzing EC lysates (Figure 1D) or
purified enzymes (Figures S1E–S1I). When measuring glycolytic
flux by using D-[5-3H]-glucose, 3PO did not further reduce
glycolysis in ECs in which PFKFB3 was silenced to nearly unde-
tectable protein levels (Figure 1A). YN1 reduced glycolysis in
PFKFB3-silenced cells slightly more (Figure S1A), in agreement
with its partial effect on PFKFB4 (Seo et al., 2011).
PFKFB3 Blockade Reduces Glycolysis Partially
and Transiently In Vivo
We also determined the effect of 3PO on glycolysis in vivo in
mice by measuring 2-[1-14C]-deoxy-D-glucose (2-[1-14C]-DG)
uptake as an indirect parameter of glycolysis. 3PO lowered
2-[1-14C]-DG uptake by 38% and 41% in the diaphragm and
heart, but only transiently during 6 hr (Figure 1E). However, a sec-
ond administration of 3PO 24 hr later comparably reduced
2-[1-14C]-DG uptake (Figure 1E). Intravenous injection of
[U-13C]-glucose and analysis of 13C-lactate enrichment in the
blood by gas chromatography-mass spectrometry (GC-MS)
confirmed the transient reduction in glycolysis upon 3PO injec-
tion (Figure 1F).
PFKFB3 Blockers Reduce EC Proliferation
and Migration In Vitro
In ECmonolayers, 3PO reduced [6-14C]-glucose incorporation in
RNA, a process involving the nonoxidative branch of the pentose
phosphate pathway (non-oxPPP) that generates pentoses for
nucleotide synthesis (Figure 1G). 3PO also decreased EC prolif-
eration (Figure 1H), in agreement with PFKFB3 silencing data (De
Bock et al., 2013b). Instead, 3PO increased the fraction of quies-
cent ECs (Figure 1I). This effect was reversible, as removal of
3PO restored the fraction of cycling cells (Figure 1I). In accor-
dance, glycolysis was 40% lower in contact-inhibited quiescent
ECs than in cycling ECs (Figure 1J). To study EC migration in the
absence of confounding effects of proliferation, we treated ECs
with mitomycin C (MitoC) to inhibit proliferation. 3PO reduced
MitoC-treated EC migration in a scratch wound and modified
Boyden chamber assay, and the effects were reversible upon
washout of 3PO (Figure 1K; Figure S1J). Similar data were ob-
tained for YN1 (Figures S1K and S1L).
PFKFB3 Blockers Impair Vessel Sprouting In Vitro
To study the effect of PFKFB3 blockers on vessel sprouting, we
used EC spheroids. Similar to that in vivo, a tip cell with filopodia-
like protrusions takes the lead, while proliferating stalk cells elon-
gate the sprout. PFKFB3 was essential for vessel outgrowth, as
both 3PO and YN1 shortened sprout length and decreased
sprout numbers (Figures 2A–2D; Figures S2A, S2B, S2D, and
S2E), similar to the effect induced by PFKFB3 silencing (De
Bock et al., 2013b). 2DG also reduced vessel sprouting (Figures
S2C–S2E), but unlike 3PO-treated spheroids that retained a
healthy morphology, 2DG-treated spheroids disintegrated and
eventually died, as revealed by TO-PRO 3 staining (Figures
S2F–S2H), indicating that near-complete inhibition of glycolysis
causes cellular demise and death. Counting of Hoechst 33342-Cstained nuclei revealed that 3PO reduced EC numbers in
vascular sprouts (Figures 2E–2G). 3PO also decreased the incor-
poration of bromodeoxyuridine (BrdU) in spheroid sprout ECs
(Figure 2H), indicating that blockade of PFKFB3 impairs sprout-
ing at least partially via reducing EC proliferation. 3PO also
impaired ECmigration, as it reduced sprouting after MitoC treat-
ment (Figures 2I and 2J). Furthermore, 3PO impeded capillary
tube formation (Figures S2I and S2J).
PFKFB3 increases glycolysis but decreases the oxidative
pentose phosphate pathway (oxPPP) flux (Herrero-Mendez
et al., 2009). This pathway with its rate-limiting enzyme glucose-
6-phosphate dehydrogenase (G6PD) generates NADPH, used
to reduce oxidized glutathione for antioxidant defense. Notably,
3PO increased the oxPPP flux (Figure 2K) and, consistent with
previous reports that the oxPPP promotes angiogenesis (De
Bock et al., 2013a; Leopold et al., 2003), blocking the oxPPP by
6-aminonicotinamide (6AN) decreased vessel sprouting (Figures
2L and 2M). However, this increase did not explain the impaired
vessel sprouting phenotype by 3PO, since blocking the oxPPP
by 6ANdid not abrogate the antisprouting activity of 3PO (Figures
2L and 2M). Furthermore, addition of sodium pyruvate at a con-
centration that increases oxygen consumption (De Bock et al.,
2013b) did not rescue the impaired vessel sprouting in 3PO-
treated spheroids (Figures S2K and S2L), indicating that
diminishing glycolysis by 3PO did not reduce vessel sprouting
by diminishing entry of glycolytic intermediates into the tricarbox-
ylic acid (TCA) cycle for oxidative glucose metabolism.
PFKFB3 Blockade Does Not Alter the Expression
of Tip- or Stalk-Enriched Genes
We analyzed if PFKFB3 impeded tip or stalk cell formation by
reducing the expression of VEGF receptor 2 (VEGFR2) and
Dll4, known to influence tip versus stalk cell formation, respec-
tively (Geudens and Gerhardt, 2011; Potente et al., 2011). How-
ever, RT-PCR analysis revealed that 3PO did not alter the
expression of tip or stalk cell-enriched genes (Figure 2N).
Indeed, 3PO did not affect transcript levels of Dll4 or of the
Notch1 target genes HES1, HEY1, and HEY2. Expression of
VEGFR2 was also not affected by 3PO at the mRNA or protein
level (Figure 2N; Figure S2M). Since 2DG interferes with glyco-
sylation by affecting the hexosamine biosynthetic pathway, a
side pathway of glycolysis, we examined if 3PO had similar
effects. However, VEGFR2 was detected as a fully glycosylated
230 kDa form in 3PO-treated ECs (Figure S2M), suggesting that
glycosylation was not impaired. Fluorescence-activated cell
sorting (FACS) analysis also failed to reveal a difference in
VEGFR2 levels on the cell surface (Figure S2N). Overall, consis-
tent with PFKFB3 loss-of-function studies in ECs (De Bock
et al., 2013b), the impaired vessel sprouting by 3PO was not
attributable to a change in the expression of tip versus stalk
cell signature.
PFKFB3 Blockers Impair Vessel Sprouting in Zebrafish
To explore the functional in vivo relevance of PFKFB3 inhibition,
we used fli1:EGFPy1 zebrafish embryos expressing GFP in ECs
and focused on intersomitic vessels (ISVs), which branch off
from the dorsal aorta in a ventral-to-dorsal direction and estab-
lish the dorsal longitudinal anastomosing vessel (DLAV). We
analyzed only viable embryos without developmental defectsell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc. 39
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Figure 2. Pharmacological Blockade of PFKFB3 by 3PO Impairs Sprouting In Vitro
(A and B) Representative bright-field micrographs of control (A) and 3PO-treated (B) EC spheroids, showing reduced vascular sprouting in spheroids in the
presence of the PFKFB3 inhibitor 3PO (B). Scale bars: 50 mm.
(C and D) Morphometric quantification of EC spheroid sprouting, revealing that blockade of PFKFB3 by 3PO reduced the number of sprouts per spheroid (C) and
total sprout length (D) (mean ± SEM; n = 30; *p < 0.01).
(E and F) Representative fluorescence photographs of Hoechst 33342-stained EC spheroids (E), showing a reduced number of EC nuclei in the sprouts of 3PO
treated spheroids (F).
(G) Quantification of Hoechst 33342-stained ECs, showing that 3PO treatment reduces the number of nuclei per sprout (mean ± SEM; n = 30 spheroids; *p <
0.001).
(H) Quantification of BrdU+ ECs in spheroid sprouts, showing reduced proliferation upon PFKFB3 blockade by 3PO (mean ± SEM; n = 23 spheroids; *p < 0.005).
(I and J) Morphometric quantification of EC spheroid sprouting, revealing that blockade of PFKFB3 by 3PO reduced the total sprout length (I) and number of
sprouts per spheroid (J) even after MitoC-induced mitotic arrest (mean ± SEM; n = 30; *p < 0.05 versus ctrl and &p < 0.05 versus MitoC).
(K) Quantification of oxPPP, showing increased flux upon 3PO treatment (mean ± SEM; n = 4; *p < 0.04).
(L and M) Morphometric quantification of vessel sprouting from EC spheroids upon 6AN treatment, showing that blockade of the oxPPP affects neither the 3PO-
induced reduction of the number of sprouts per spheroids (L) nor the total sprout length (M) (mean ± SEM; n = 20; *p < 0.0001).
(N) mRNA expression analysis of DLL4, HES1, HEY1, HEY2, and VEGFR2, showing unaltered expression after PFKFB3 blockade (mean ± SEM; n = 3; p = NS).
See also Figure S2.
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Figure 3. Pharmacological Blockade of PFKFB3 Impairs Vascular Development in Zebrafish Embryos
(A–D) Confocal images of GFP+ vessels in 35 hpf fli1:EGFPy1 embryos treatedwith DMSO (ctrl) (A), 3PO (20 mM) (B), 3PO (30 mM) (C), or 3PO (40 mM) (D) from 20 hpf
onward, showing impaired outgrowth of ISVs (arrows) and defective formation of the DLAV (arrowheads). Scale bars: 50 mm.
(E–J) Confocal images of 48 hpf fli1:EGFPy1 embryos after intracardiac angiography with rhodamine-labeled dextran, showing that compared to control embryos,
3PO treatment (40 mM; from 20 hpf onward) reduced ISV perfusion. Control, GFP signal (E); control, rhodamine-dextran signal (F); control, merge (G); 3PO treated,
GFP signal (H); 3PO treated, rhodamine-dextran signal (I); 3PO treated, merge (J).
(K) Quantification of perfused ISVs in Tg(kdrl:EGFP;gata1:DsRed) zebrafish (mean ± SEM; n = 3 for control and n = 4 for 3PO; *p < 0.001).
(L–N) Confocal images of GFP+ vessels in 35 hpf fli1:nEGFPy7 zebrafish embryos treated with DMSO (ctrl) (L) or 3PO (40 mM) (M) from 20 hpf onward, showing that
3PO reduced EC numbers in the ISVs (arrows) and in the DLAV (arrowheads), and quantification (N) (mean ± SEM; n = 8 for control and 6 for 3PO; *p < 0.0001).
(O and P) Pseudocolor lookup table (LUT) high-magnification confocal images of GFP+ ISVs in 35 hpf fli1:EGFPy1 zebrafish embryos showing that compared to
controls (O), embryos treated with 3PO (45 mM) have fewer and shorter filopodia (P).
(Q and R) Quantification of the filopodia length (Q) and number (R) (filopodia length: n = 30 for ctrl and n = 20 for 3PO; *p < 0.0001; filopodia number per ISV: n = 4;
*p < 0.005). See also Figure S3 and Movie S1.
Cell Metabolism
PFKFB3 Blockade Reduces Pathological Angiogenesisand with an intact circulation (Figure S3A–S3D). When treating
embryos with 3PO from 20 hr postfertilization (hpf) onward, just
prior to the onset of ISV sprouting, 3PO dose dependently
impaired ISV sprouting (Figures 3A–3D). At 40 mM, only <5% of
the embryos formed ISVs, but these vessels had perfusion de-
fects (see below). Time-lapse video imaging of 3PO-treated
embryos showed that the ISVs failed to grow out normally and
established only an incomplete DLAV (Movie S1). At the highest
concentration of 3PO (40 mM), a fraction of ISVs stalled midway,
exhibiting blunt ends without side branches or anastomoses,
and failed to form a DLAV (Figure 3D). Withdrawal of 3PO reiniti-
ated branching, showing that 3PO did not cause irreversible EC
demise (Figures S3E–S3G). Similar results were obtained for
YN1 (Figures S3H–S3J). Angiography after intracardiac injection
of rhodamine-labeled dextran showed that 3PO reduced
the number of perfused ISVs (Figures 3E–3J). Analysis of
Tg(kdrl:EGFP;GATA1:DsRed) zebrafish, in which vessels areCGFP+ and erythrocytes are DsRED+, confirmed these findings
(Figure 3K).
Counting of EC nuclei in fli1:nEGFPy7 zebrafish embryos, ex-
pressing GFP in endothelial nuclei, showed that 3PO
decreased EC numbers in the DLAV (Figures 3L–3N). In addi-
tion, time-lapse video imaging revealed that 3PO altered the
leading edge of the vascular front, where tip cells reside. In
contrast to the rapidly advancing and dynamically exploring
vascular front in control embryos, tip cells in 3PO-treated em-
bryos were less dynamic and exploratory and moved more
slowly, almost creeping forward (Movie S1). In control em-
bryos, tip cells were polarized in a rear-to-front direction, often
projecting at the leading edge two to three ‘‘foot-like’’ cyto-
solic protrusions (2–3 mm wide) from where multiple, rapidly
moving, and highly motile long filopodia extended (Figures
3O–3R). By contrast, in 3PO-treated embryos, tip cells pro-
jected shorter, thinner, and more blunt-ended ‘‘foot-like’’ell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc. 41
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Figure4. PharmacologicalPFKFB3Blockade
Impairs Vascular Development in Mice
(A and B) Confocal images of isolectin-B4-stained
(gray) retinal vessels of postnatal day 5 (P5) pups at
high magnification, showing, as compared to
DMSO-treated mice (A), reduced vascular branch-
ing in 3PO-treated mice (50 mg/kg) (B). Scale bars:
50 mm.
(C–E)Quantificationof theeffectof3POtreatmenton
thenumberofbranchpoints (C), radial expansion (D),
and the number of distal sprouts with filopodia (E) in
the retinal vasculature of 3PO-treated mice (mean ±
SEM; n = 3 for ctrl and n = 5 for 3PO; *p < 0.001).
(F and G) Triple staining for Erg (blue), isolectin B4
(red), and BrdU (green) at the vascular front of the
retinal plexusof control (F) and 3PO-treated (G)mice
confirmed that ECproliferationwas reduced in 3PO-
treated mice (G) (mean ± SEM; n = 3; p < 0.05).
Arrows: proliferating ECs.
(H) Quantification of BrdU+ Erg+ cells/mm2 retinal area, revealing lower proliferation of retinal ECs after 3PO treatment (mean ± SEM; n = 3; *p < 0.05). Scale
bars: 50 mm. See also Figure S4.
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(Figures 3O–3R).
PFKFB3 Blockers Impair Vessel Sprouting in the Mouse
Retina
We also studied the effects of PFKFB3 blockade on vascular
sprouting in the postnatal retina, a widely used mouse model
to characterize tip and stalk cell phenotypes. Treatment of
pups with 3PO at postnatal days 1–4 (P1–P4) reduced the num-
ber of branch points (Figures 4A–4C), the radial expansion of the
vascular plexus (Figure 4D), and the number of distal sprouts
with filopodia (Figure 4E). YN1 also reduced vessel branching
in the retina (Figures S4A–S4D). Staining of retinal flat mounts
for isolectin B4, BrdU, and Erg (an EC-specific nuclear transcrip-
tion factor) revealed that fewer Erg+ BrdU+ ECs were present in
the vascular plexus in 3PO-treated mice, suggesting that EC
proliferation was impaired (Figures 4F–4H). Confirming the
gene expression data in EC monolayers, 3PO did not affect the
expression of the tip cell-enriched marker Pdgfb in retinal tip
cells (Figures S4E and S4F).
Blocking PFKFB3 Inhibits Vascular Hyperbranching
We then explored if PFKFB3 blockade counteracted vascular
hyperbranching. VEGFR1 (Flt1) is an inhibitor of vascular
branching and, consistent with previous findings (Krueger
et al., 2011), flt1 knockdown (flt1KD) caused ISV hyperbranching
(Figures 5A and 5B). 3PO normalized ISV hyperbranching in a
large fraction of flt1KD embryos and reduced the severity of
vascular overgrowth (Figures 5C and 5D). While 64% of con-
trol-treated flt1KD embryos exhibited signs of severe ISV hyper-
branching in at least 4 out of 10 ISVs per embryo, only 20% of
3PO-treated flt1KD embryos showed this phenotype, and up to
29% of them formed completely normal ISVs. 3PO also reduced
ISV side branches in flt1KD embryos (side branches per ISV:
100% ± 10% for flt1KD controls versus 54% ± 10% for 3PO-
treated flt1KD; n = 3 experiments, each with >8 embryos per
condition; p < 0.01 by univariate test). We also analyzed ISV
perfusion. In control embryos, intracardiac angiography with
rhodamine-labeled dextran showed that PFKFB3 blockade42 Cell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc.impaired vessel lumen formation and perfusion (see above). In
contrast, ISVs in Flt1-silenced (flt1KD) embryos had an enlarged
lumen, but PFKFB3 blockade largely normalized ISV lumen size
in flt1KD embryos (Figures S5A–S5F) without impairing vessel
perfusion (Figure S5G).
We also induced vascular hyperbranching by blocking
Dll4/Notch signaling (Hellstro¨m et al., 2007). In EC spheroids,
N-(N-(3,5-Difluorophenacetyl)-L-alanyl)-S-phenylglycine t-butyl
ester (DAPT) increased the number and length of the vessel
sprouts, but this hypersprouting was abrogated by 3PO (Fig-
ures S5H–S5K). 3PO also rescued vascular hyperbranching in
zebrafish embryos upon silencing of Dll4 (Figures S5L–S5O)
or in the retina upon treatment of neonatal mice with DAPT (Fig-
ures 5E–5H).
PFKFB3 Blockade Amplifies the Antiangiogenic Effect
of VEGFR Blockers
VEGF blockade is a clinically approved antiangiogenic strategy.
The VEGFR tyrosine kinase inhibitor SU5416 caused dose-
dependent vascular defects in zebrafish embryos, character-
ized by progressive impairment and stalling of ISVs and lack
of DLAV formation. At a maximal concentration (1 mM),
SU5416 prevented the outgrowth of 30% of the ISVs (Fig-
ure 5I). These defects were not only more severe, but also
occurred at a higher incidence when increasing the dose of
SU5416 (Figure 5I).
To evaluate if PFKFB3 blockade enhanced the antiangiogenic
effect of VEGFR inhibition, we treated embryos with suboptimal
doses of SU5416 (0.1 or 0.5 mM) and 3PO (20 or 30 mM), which
alone only induced a negligible impairment of ISV outgrowth in
a minority of embryos (Figures 5J–5L). However, the combina-
tion of both compounds at suboptimal doses aggravated the
vessel defects in most embryos (Figures 5I and 5M). Even
when a high dose of SU5416 (1 mM) was used that prevented
the formation of half of the ISVs, the combination with 3PO
(30 mM) further aggravated this phenotype, abrogating ISV devel-
opment in nearly all embryos (Figure 5I). Overall, blockade of
glycolysis amplified the efficacy of targeted VEGF inhibition in
blocking angiogenesis.
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Figure 5. PFKFB3 Blockade Inhibits
Vascular Hyperbranching In Vivo
(A–D) Confocal images of 72 hpf fli1:EGFPy1 em-
bryos. As compared to the normally patterned ISV
in a control embryo (A), ISVs hyperbranch in flt1KD
embryos (arrowheads in B). Treatment of flt1KD
embryos with 3PO (30 mM) largely normalized the
vascular hyperbranching phenotype (C). Shown in
(D) is the incidence of flt1KD embryos with no, mild,
or severe vascular hyperbranching, revealing that
3PO reduced vascular hyperbranching (n = 12;
*p < 0.00001). Scale bars: 50 mm.
(E–G) Confocal images of the retinal vasculature
after treatment with control (E), DAPT (F), or
DAPT + 3PO (G), showing that DAPT increased the
number of branch points and that 3PO abolished
the hyperbranching induced by DAPT.
(H) Quantification of the number of branches
(mean ± SEM; n = 5 for DAPT and 3PO+DAPT,
n = 8 for ctrl; *p < 0.001 versus control (gray), &p <
0.05 versus DAPT).
(I) Quantification of the average incidence of indi-
cated ISV phenotypes for 10 ISVs scored per em-
bryo upon single or combined treatment with the
indicated doses of 3PO and/or SU5416. Complete
ISV, ISVs formed normally and completely; partial
ISV (above midline), ISVs formed at least until or
partially above the horizontal midline without
reaching the dorsal roof level; partial ISV (below
midline), ISVs were severely underdeveloped and
failed to reach the horizontal midline; absent ISV,
ISVs completely failed to sprout. n values per
condition are indicated under the bars.
(J–M) Confocal images of GFP+ vessels in 35 hpf
fli1:EGFPy1 embryos, showing a control embryo (J)
and a minor impairment of ISV development when
treating embryos with a submaximal dose of 3PO
(K) or the VEGFR tyrosine kinase inhibitor SU5416
(L) but severe vascular defects and near-complete
abrogation of ISV formation in embryos treated
with the combination of both inhibitors (M). Scale
bars: 50 mm. See also Figure S5.
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Angiogenesis
We tested if PFKFB3 blockade inhibited choroidal neovasculari-
zation (CNV), amodel of age-relatedmaculardegeneration (AMD)
(Van de Veire et al., 2010). The lesions in this model are largely
vascular in nature, allowing us to assess antiangiogenic effects
of 3PO. Starting from 1 day after laser burn injury of the Bruch’s
membrane to induce CNV, mice received a daily dose of vehicle
or 3PO.Quantification of CNV lesions upon injectionwith fluores-
cein isothiocyanate (FITC)-conjugated dextran at 14 days after
laser injury showed that 3PO dose dependently reduced the
CNV lesion volume (Figures 6A–6C). We also evaluated if 3PO
amplified the antiangiogenic activity of the anti-VEGFR2 mono-
clonal antibody (mAb) DC101 (Van de Veire et al., 2010). When
using a suboptimal dose of DC101 (12.5 mg/kg, 33 per week),
CNV was reduced by 38%, while the combination of DC101
plus 3PO caused a decrease of CNV by 67% (Figure 6D).
We confirmed the antiangiogenic activity of 3PO by using other
models of pathological angiogenesis. We first used the oxygen-
inducedmodelof retinopathyofprematurity (ROP),which isbased
on the exposure ofmouse pups to hyperoxia during a phasewhenCtheir retinal vasculature is still developing, from P7–P12. This
causes capillary depletion and vascular rarefication and, upon re-
turn to room air, results in retinal ischemia and, subsequently, in
the formation of proliferative vascular tufts by P17–P21 (Scott
and Fruttiger, 2010). Like in CNV, the lesions in the ROP model
are primarily vascular in nature. Treatment of pups with 3PO dur-
ing thephaseof vascular proliferation fromP12 toP17reduced the
formation of vascular tufts at P17 (Figures 6E–6G).
We also used two inflammation models, e.g., a skin psoriasis
model and an inflammatory bowel disease model, since inflam-
matory disorders are characterized by increased angiogenesis
(Wynn et al., 2013). A previous study reported that 3PO treatment
reduced skin epithelial hyperplasia and inflammation, induced by
local application of the immune activator imiquimod (IMQ), but
this study did not analyze the effects on angiogenesis (Telang
et al., 2012). Confirming previous findings, 3PO reduced the
epidermal hyperplasia (Figure S6A), the spleen weight, another
measure of inflammation (Figure S6B), and the number of CD3+
lymphocytes in the lesions (Figure S6C). Importantly, 3PO also
decreased thedensity ofCD105+ vessels in the epidermal lesions
(Figures 7A–7D).ell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc. 43
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Figure 6. Blockade of PFKFB3 Reduces
Pathological Angiogenesis: Ocular Models
(A and B) FITC-dextran choroidal flatmounts of
control (A) or 3PO-treated mice (B), revealing
fewer choroidal neovessels after 3PO treatment
(B). The images are 3D isosurface renderings from
z stacks of all individual optical sections through
the neovascular lesion, as made by confocal laser
scanning microscopy. Scale bars: 50 mm.
(C) 3PO dose dependently reduced CNV volume
(estimated marginal mean ± SEM; n = 16 for ctrl,
n = 16 for 38 mg/kg 3PO, and n = 14 for 50 mg/kg
3PO; two independent experiments; *p < 0.04 by
general linear model univariate analysis, consid-
ering experiment as covariate).
(D) The combination treatment of 3PO (50 mg/kg)
plus a submaximal dose of the anti-VEGFR2 mAb
DC101 reduced the CNV neovascular area more
than eachmonotherapy alone (mean ±SEM; n = 18
for ctrl, n = 7 for 3PO, n = 9 for DC101, and n = 8 for
3PO+DC101; *p < 0.05 versus ctrl or as indicated).
(E and F) Retinal flatmounts of ROP mice treated
withDMSO (E) or 3PO (F) (70mg/kg) andstained for
isolectin B4, revealing reduced formation of
vascular tufts (arrowheads) after 3PO (70 mg/kg)
(F). Scale bars: 50 mm.
(G) Quantification of the vascular tuft area (mean ±
SEM; n = 11 for ctrl, n = 9 for 3PO; *p < 0.001).
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PFKFB3 Blockade Reduces Pathological AngiogenesisInflammatory bowel disease, induced by administration of
dextrane sulfate sodium (DSS), is also characterized by patho-
logical angiogenesis (Hindryckx et al., 2010). Quantification of
the disease activity index (DAI), which scores body weight
loss, stool consistency, and blood in the stool and anal region,
revealed that 3PO reduced disease severity (Figure 7H). Hema-
toxylin and eosin staining (H&E) showed that 3PO-treated mice
had less-severe acute colitis (Figures 7E–7G). To quantify the
histological signs of colitis, we used a histologic scoring method,
taking into account the severity of inflammatory cell infiltration
(dispersed, focal, or widespread), the extent of injury (mucosal,
submucosal, or transmural), and crypt damage (basal, luminal,
or entire crypt loss) (Cummins et al., 2008). This analysis
confirmed that 3PO reduced the severity of colitis (histological
score, median value: 10 for control versus 6 for 3PO; n = 11 for
control and n = 10 for 3PO; p = 0.0004), and decreased CD45+
cell infiltration in the (sub)mucosa and muscularis externa (Fig-
ure 7I). 3PO also decreased the area of CD105+ vessels in the in-
flamed mucosa, submucosa, and muscularis externa (Figures
7J–7M).
DISCUSSION
Glycolysis: An Overlooked Target in Angiogenesis?
ECs rely on glycolysis and derive up to 85% of their ATP from
glycolysis, while PFKFB3-driven glycolysis regulates EC prolifer-44 Cell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc.ation and migration (De Bock et al.,
2013b). We now also show that ECs in-
crease glycolysis when shifting from
quiescence to proliferation andmigration.
Glycolysis is required for cell proliferation,not only by providing ATP, but also by generating glycolytic inter-
mediates that are used for the synthesis of macromolecules
necessary for cell mass duplication during division (Lunt and
Vander Heiden, 2011). In addition, glycolysis is required for EC
motility, in part by compartmentalizing PFKFB3 and other glyco-
lytic enzymes in lamellipodia and by concentrating these glyco-
lytic enzymes with F-actin at leading membrane ruffles (De Bock
et al., 2013b). The high glycolytic flux in ECs, their dependence
on this pathway to generate most of the ATP, and the increased
glycolysis during EC proliferation and migration, together with
the genetic findings that loss of PFKFB3 in ECs affects tip and
stalk cells (De Bock et al., 2013b), render glycolysis an attractive
target for therapeutic inhibition of angiogenesis.
PFKFB3 Blockade Reduces Physiological
and Pathological Angiogenesis
We previously reported that genetic silencing of PFKFB3 re-
duces vessel formation in physiological conditions (De Bock
et al., 2013b), but it remained untested if pharmacological
blockade of PFKFB3 could also impair pathological angiogen-
esis. 3PO phenocopied the effects of PFKFB3 silencing in ECs
in vitro and of PFKFB3 inactivation in ECs in vivo (De Bock
et al., 2013b). Indeed, 3PO impaired vessel sprouting in EC
spheroids by reducing EC proliferation and migration, impeded
filopodia formation, and EC accumulation in ISVs in zebrafish
and caused vascular hypobranching and outgrowth in the
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Figure 7. PFKFB3 Blockade Reduces Path-
ological Angiogenesis: Inflammation
Models
(A–C) Representative images of CD105 staining of
untreated skin (A), IMQ-DMSO-treated skin (ctrl)
(B), and IMQ-3PO-treated skin (3PO) (C). Scale
bars: 100 mm.
(D) Reduced CD105+ vascular area in the dermis
upon 3PO treatment (mean ± SEM; n = 7 for un-
treated, n = 9 for IMQ-DMSO and IMQ-3PO; *p <
0.001).
(E–M) DSS-induced colitis model. Representative
H&E images of untreated healthy colon (E), DSS-
DMSO-treated colon (DSS-ctrl) (F), and DSS-3PO-
treated colon (50 mg/kg) (G). Scale bars: 200 mm.
(H) Reduced disease activity index (DAI) score
upon 3PO treatment (median; n = 11 for DSS-
DMSO, n = 10 for DSS-3PO; *p < 0.0001). (I)
Reduced CD45+ area in the mucosa, submucosa,
and muscularis externa of the colon upon 3PO
treatment (mean ± SEM; n = 3 for untreated, n = 11
for control, and n = 10 for 3PO; *p < 0.003). (J)
Reduced CD105+ vascular area in the mucosa,
submucosa, and muscularis externa of the colon
upon 3PO treatment (mean ± SEM; n = 3 for un-
treated, n = 11 for DSS-DMSO, and n = 10 for DSS-
3PO; *p < 0.004). Representative images of CD105
staining of untreated healthy colon (K), DSS-
DMSO-treated colon (DSS-ctrl) (L), and DSS-3PO-
treated colon (M). Scale bars: 100 mm. See also
Figure S6.
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PFKFB3 Blockade Reduces Pathological Angiogenesismouse retina by decreasing EC proliferation and tip cell
behavior. The finding that 3PO impaired lumen formation (a pro-
cess requiring actin cytoskeleton changes; Sacharidou et al.,
2012) is in agreement with findings that PFKFB3 regulates actin
cytoskeleton remodeling processes (De Bock et al., 2013b).
3PO also reduced vascular hyperbranching induced by inhibi-
tion of Notch or VEGFR1 signaling in zebrafish embryos. In addi-
tion, 3PO largely normalized vascular hypersprouting in EC
spheroids and the mouse retina, induced by the Notch signaling
blocker DAPT. Moreover, 3PO reduced pathological neovascu-
larization in ocular and inflammatory models in the mouse and
amplified the antiangiogenic activity of a VEGF receptor tyrosine
kinase inhibitor and anti-VEGF receptor 2 in the zebrafish and
CNV mouse model, respectively. Together, inhibition of PFKFB3
by 3PO reduces vessel formation in physiological and patholog-
ical conditions in the models tested.
Partial and Transient Reduction of Glycolysis
Previous antiglycolytic anticancer strategies attempted to block
glycolysis completely and permanently, but these approaches
also caused adverse effects (Granchi and Minutolo, 2012). InCell Metabolism 19, 37–agreement, our 2DG experiments show
that more complete, sustained inhibition
of glycolysis induces toxic effects in
cultured ECs. In contrast, 3PO reduced
glycolysis only partially, inducing EC
quiescence without causing EC death
in vitro. Likewise, 3PO reduced glycolysis
only partially and transiently in vivo, butwithout inducing permanent refractoriness, since a second
3PO administration 24 hr later reduced glycolysis again to the
same level as the first treatment. Thus, a partial and daily tran-
sient decrease of glycolysis sufficed to suppress pathological
neovascularization. It remains to be studied whether 3PO treat-
ment in vivo has acceptable tolerability.
The transient effect of 3PO is in agreement with its short half-
life (30 min), rapid clearance (2,312 ml/kg/min), low Cmax
(113 ng/ml) and low area under the concentration-time curve
from zero to infinity (AUC0-inf; 36 ng/hr/ml) (AUC0-inf refers to
the actual body exposure to 3PO after administration of a
dose of 3PO) (Clem et al., 2013). With the concentrations
used, 3PO blocked PFKFB3 completely, since 3PO failed to
further reduce glycolysis in ECs in which PFKFB3 was silenced
to nearly undetectable levels. Despite full blockade of PFKFB3,
glycolysis was only decreased by 35%–40%. Similar data were
obtained when silencing PFKFB3 (De Bock et al., 2013b). The
reason for the partial effect likely relates to the fact that 3PO
blocks an activator of a key enzyme in glycolysis (e.g.,
PFK-1). Hence, PFKFB3 blockade has a ceiling level in its abil-
ity to inhibit glycolysis.48, January 7, 2014 ª2014 Elsevier Inc. 45
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PFKFB3 Blockade Reduces Pathological AngiogenesisPFKFB3 Blockade: A Different Therapeutic
Antiglycolytic Paradigm
Past antiglycolytic therapies faced challenges of cross-inhibition
of other glycolytic targets, off-target effects, poor membrane
permeability, and inability of compounds to efficiently antago-
nize abundant glycolytic substrates (Granchi and Minutolo,
2012). For instance, 2DG must compete with mM levels of
glucose in the blood, necessitating delivery of high (toxic)
amounts (Granchi and Minutolo, 2012). Nonetheless, cancer
patients receiving 2DG had a progressive disease and suffered
adverse effects (Granchi and Minutolo, 2012; Raez et al.,
2013). Some of the side effects were attributed to the fact that
these strategies block not only glycolysis, but also other glucose
metabolism pathways (Granchi and Minutolo, 2012). Another
reason is that these approaches inhibit glycolysis nearly
completely and permanently, inducing ATP depletion and
toxicity (Granchi and Minutolo, 2012). Indeed, human genetic
studies reveal that a decrease in glycolysis due to hereditary mu-
tations in glycolytic genes is well tolerated, as long as the
decreased glycolysis levels do not deplete ATP levels (Climent
et al., 2009).
PFKFB3 blockade by 3PO differs from these antiglycolytic
approaches in various aspects. Firsty, it inhibits a defined
intracellular enzyme, requiring much lower (mM) inhibitor con-
centrations than the high (mM) concentrations of 2DG needed
to compete with the mM plasma glucose levels (Franc¸ois
et al., 1987). Second, unlike 2DG and related drugs, which
block glucose metabolism high up in the pathway, PFKFB3
blockade inhibits a defined downstream target, which specif-
ically reduces glycolytic flux, without abrogating glycolytic
side pathways such as the oxidative PPP (oxPPP), necessary
for the production of NADPH to secure redox homeostasis. In
fact, 3PO increased the oxPPP flux, but this change did not
explain the antiangiogenic activity of 3PO. Third, 3PO and
YN1 did not inhibit other glycolytic enzymes, tested by using
recombinant enzymes or 3PO-treated EC extracts. Fourth, the
KM of PFKFB3 for its substrate fructose-6-phosphate (F6P) is
97 mM, while the Ki for competitive inhibition by 3PO is
25 mM, and 3PO has no effect on PFK-1, which shares an iden-
tical substrate, F6P (Clem et al., 2008). Fifth, 3PO did not cause
EC death.
3PO Blocks Hyperglycolysis during EC Proliferation
and Migration
Of the maximal amount of glycolysis that ECs can generate,
they use 40% to proliferate and migrate, reserving 60% for
maintenance homeostasis, in line with findings that proliferation
only requires 30% of ATP production (Locasale and Cantley,
2010). Lowering glycolysis by 40% through 3PO treatment
impaired EC proliferation and migration. This, however, did
not cause EC death, but promoted reversible quiescence.
PFKFB3 blockade thus reduced the hypermetabolism that is
induced when ECs switch from quiescence to proliferation
and migration.
Possible Medical Implications
PFKFB3 blockade decreased pathological angiogenesis in in-
flammatory and ocular disease models. Choroidal neovasculari-
zation (a preclinical model of wet AMD) and retinopathy of46 Cell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc.prematurity are blinding disorders, caused by excessive growth
of retinal vessels (Cavallaro et al., 2013; Miller et al., 2013; Stew-
art, 2012). Anti-VEGF therapy has beneficial effects in AMD and
ROP patients, but does not attain durable treatment-free cessa-
tion of the disease (Darlow et al., 2013; Niranjan et al., 2012; Ro-
fagha et al., 2013). In addition, one-third of patients with wet
AMD have poor visual outcome, and13% lost more vision after
intraocular anti-VEGF treatment (Lalwani et al., 2009). Our find-
ings that 3PO reduces vascular lesions in both ocular disorders
and enhances the antiangiogenic effect of the anti-VEGFR2 in
theCNVmodelmaywarrant further study of a possible therapeu-
tic use of PFKFB3 blockers.
EXPERIMENTAL PROCEDURES
More detailed methods are described in the Supplemental Experimental
Procedures.
Cellular Assays
Freshly isolated primary HUVECswere used for evaluation of metabolism, pro-
liferation, migration, matrigel assay, spheroid capillary sprouting assays, and
cell cycle status. Except for Figure 1A, we used the maximal concentration
of 3PO that reversibly impaired in vitro EC responses, ranging between 15
and 20 mM.
RNA Expression Analysis
RNA expression analysis was performed by TaqMan qRT-PCR or in situ
hybridization.
Metabolism Assays
Glycolysis, glucose incorporation into RNA, and oxidative pentose phosphate
pathway flux were determined by incubating cells with radioactive-labeled
tracer glucose. Briefly, 3H2O formation was a measure for glycolytic flux.
14CO2 production was a measure for oxidative pentose phosphate pathway
flux, and 14C counts in isolated RNA was a measure for glucose incorporation.
Fructose-2,6-bisphosphate levels in cell lysates were determined as
described (Van Schaftingen et al., 1982). Oxygen consumption and lactate
production were measured using the Seahorse XF24 analyzer. Energy balance
was calculated as ([ATP] + ½[ADP]) / ([ATP] + [ADP] + [AMP]) based on high-
performance liquid chromatography (HPLC) measurement of AMP, ADP,
and ATP levels in cell extracts.
Proliferation
Proliferation was quantified by incubating cells with [3H]-thymidine. The
amount of [3H]-thymidine incorporated into DNA wasmeasured by scintillation
counting.
Migration
Migration was evaluated using scratch wound or Boyden chamber migration
assays. To evaluate responses in the absence of proliferation, MitoC-treated
ECs (0.5–1 mg/ml for 24 hr) were used.
Spheroid Capillary Sprouting Assay
ECs were incubated overnight in hanging drops to form spheroids, embedded
in collagen, and cultured for 24 hr (with addition of compounds as indicated) to
induce sprouting. Cultures were fixed with 4% paraformaldehyde (PFA) and
analyzed.
Matrigel Assay
ECs were plated on top of polymerized Matrigel Basement Membrane Matrix
in M119 full medium containing 3PO or vehicle. After 6 hr, the network was
fixed using 4% PFA.
Cell Cycle Analysis
Cell cycle analysis was determined by flow cytometry based on the DNA and
RNA content as stained for with Hoechst and Pyronin Y.
In Vivo Metabolism
Glycolytic flux in vivo was assessed by mass spectrometry detection of
13C-lactate in the plasma, collected 10 min after tail vein injection of [U-13C]
glucose. Glucose uptake in vivo was assessed by measuring the radiolabel
content of the heart and diaphragm, harvested 1 hr after intravenous bolus in-
jection of the mice with 2-deoxy-D-glucose, 2-[1-14C].
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Zebrafish
Tg(fli1:EGFP)y1 or Tg(fli1:nEGFP)y7 zebrafish were subjected to morpholino
oligonucleotide injection of Dll4 or Flt1 or to treatment with inhibitors (3PO,
YN1, SU5416). Assessment of sprouting and hyperbranching of ISVs, imaging,
and morphometric quantitation was as detailed in the Supplemental Experi-
mental Procedures.
Mouse Models of Ocular Angiogenesis
CNV was induced in C57BL/6 mice by laser burn. Mice were injected intraper-
itoneally (i.p.) with 38–50 mg/kg PFKFB3 inhibitor 3PO daily with or without
treatment with anti-VEGFR2 DC101 (12.5 mg/kg i.p., 33 per week). Eyes
were enucleated 2 weeks after the laser treatment and processed for immuno-
histochemistry and neovascular morphometric analysis as described in the
Supplemental Experimental Procedures. Oxygen-induced retinopathy was
induced by exposing C57BL/6 pups to 70% oxygen from P7–P12. Pups
were then returned to normoxia and injected daily with 70 mg/kg 3PO and
euthanized at P17. Retinal flat mounts were analyzed as described in the Sup-
plemental Experimental Procedures. For analysis of neonatal retinal angiogen-
esis, mice were injected with 50 mg/kg 3PO or vehicle between P2 and P4 and
euthanized at P4 or P5; eyes were enucleated and fixed, and retinal flatmounts
were prepared for vascular analysis as described in the Supplemental Exper-
imental Procedures.
Mouse Models of Inflammation
Skin inflammation was induced by daily topical application of 5% imiquimod
cream on the back of BALB/c mice. Mice received a daily i.p. dose of
50 mg/kg 3PO. After 4 days, skins were resected for analyses as described
in the Supplemental Experimental Procedures. Acute colitis was induced
with 2.5% dextran sodium sulfate (DSS) in the drinking water for 6 days.
Mice received a daily i.p. dose of 50mg/kg 3PO. Histological scoring was as
detailed in the Supplemental Experimental Procedures. All experimental ani-
mal procedures were approved by the Institutional Animal Care and Research
Advisory Committee of the University of Leuven.
Statistics
Data represent mean ± SEM of representative experiments, unless otherwise
stated. For all in vitro and in vivo experiments, every experiment was per-
formed at least three times. For analysis of the mousemodels of angiogenesis,
the investigator assessing the outcomewas blinded to the group allocation; for
analysis of zebrafish models of angiogenesis, assessment was done by an
investigator ignorant of potential outcome. Unless otherwise indicated, statis-
tical significance between groups was calculated by standard t test with F
testing to confirm equality of variance (Prism v4.0b). Phenotype severity distri-
butions were analyzed by chi-square test. Statistical significance of DAI and
histological scoring data were determined by Mann-Whitney test. p < 0.05
was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one movie and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2013.11.008.
AUTHOR CONTRIBUTIONS
P.C., S.S., K.D.B., A.R.C., andM.G. conceived and designed the experiments.
S.S. and A.R.C. performed the inflammation and ocular models of angiogen-
esis. All in vitro experiments were performed by S.S., K.D.B., A.R.C., and
M.G. The manuscript was written by P.C., S.S., and K.D.B.
ACKNOWLEDGMENTS
We acknowledge the work of Leen Notebaert for help with the illustrations.
K.D.B., A.R.C., and B.G. are Postdoctoral Fellows of the Research Founda-
tion-Flanders (FWO); M.G. and S.S. received funding as Emmanuel Vander-
schueren fellows of the Flemish Association against Cancer (VLK); and S.S.
was funded by the Institution of Research and Innovation (IWT). The work of
P.C. is supported by a Federal Government Belgium grant (IUAP7/03), long-
term structural Methusalem funding by the Flemish Government, a ConcertedCResearch Activities Belgium grant (GOA2006/11), grants from the FWO
(G.0532.10, G.0817.11, G.0834.13, 1.5.202.10N, G.0764.10N, and
1.5.142.13N Krediet aan navorsers), the Foundation Leducq Transatlantic
Network (ARTEMIS), the Foundation against Cancer, and the ERC Advanced
Research Grant (EU-ERC269073). M.D. is supported by FWO grant
G.0598.12. M.C. is supported by the Spanish Government and the European
Union FEDER funds (SAF2011-25726), Generalitat de Catalunya-AGAUR
(2009SGR1308), and the ‘‘ICREA Academia prize.’’ P.C. declares being named
as inventor on patent applications claiming subject matter related to the results
described in this paper. J.C. is coinventor of US patent #8,088,385 (PFKFB3
inhibitors for the treatment of proliferative cancer).
Received: June 14, 2013
Revised: October 21, 2013
Accepted: November 6, 2013
Published: December 12, 2013
REFERENCES
Cavallaro, G., Filippi, L., Bagnoli, P., La Marca, G., Cristofori, G., Raffaeli, G.,
Padrini, L., Araimo, G., Fumagalli, M., Groppo, M., et al. (2013). The patho-
physiology of retinopathy of prematurity: an update of previous and recent
knowledge. Acta Ophthalmol. (Copenh.). Published online April 26, 2013.
http://dx.doi.org/10.1111/aos.12049.
Chesney, J., Mitchell, R., Benigni, F., Bacher, M., Spiegel, L., Al-Abed, Y., Han,
J.H., Metz, C., and Bucala, R. (1999). An inducible gene product for 6-phos-
phofructo-2-kinase with an AU-rich instability element: role in tumor cell
glycolysis and the Warburg effect. Proc. Natl. Acad. Sci. USA 96, 3047–3052.
Clem, B., Telang, S., Clem, A., Yalcin, A., Meier, J., Simmons, A., Rasku, M.A.,
Arumugam, S., Dean, W.L., Eaton, J., et al. (2008). Small-molecule inhibition of
6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor
growth. Mol. Cancer Ther. 7, 110–120.
Clem, B.F., O’Neal, J., Tapolsky, G., Clem, A.L., Imbert-Fernandez, Y., Kerr,
D.A., 2nd, Klarer, A.C., Redman, R., Miller, D.M., Trent, J.O., et al. (2013).
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy
against cancer. Mol. Cancer Ther. 12, 1461–1470.
Climent, F., Roset, F., Repiso, A., and Pe´rez de la Ossa, P. (2009). Red cell
glycolytic enzyme disorders caused by mutations: an update. Cardiovasc.
Hematol. Disord. Drug Targets 9, 95–106.
Cummins, E.P., Seeballuck, F., Keely, S.J., Mangan, N.E., Callanan, J.J.,
Fallon, P.G., and Taylor, C.T. (2008). The hydroxylase inhibitor dimethyloxalyl-
glycine is protective in a murine model of colitis. Gastroenterology 134,
156–165.
Darlow, B.A., Ells, A.L., Gilbert, C.E., Gole, G.A., and Quinn, G.E. (2013). Are
we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch.
Dis. Child. Fetal Neonatal Ed. 98, F170–F174.
DeBock, K., Georgiadou,M., andCarmeliet, P. (2013a). Role of endothelial cell
metabolism in vessel sprouting. Cell Metab. 18, 634–647.
De Bock, K., Georgiadou, M., Schoors, S., Kuchnio, A., Wong, B.W.,
Cantelmo, A.R., Quaegebeur, A., Ghesquie`re, B., Cauwenberghs, S., Eelen,
G., et al. (2013b). Role of PFKFB3-driven glycolysis in vessel sprouting. Cell
154, 651–663.
Ebos, J.M., and Kerbel, R.S. (2011). Antiangiogenic therapy: impact on inva-
sion, disease progression, and metastasis. Nat Rev Clin Oncol 8, 210–221.
Franc¸ois, J., Eraso, P., and Gancedo, C. (1987). Changes in the concentration
of cAMP, fructose 2,6-bisphosphate and related metabolites and enzymes in
Saccharomyces cerevisiae during growth on glucose. Eur. J. Biochem. 164,
369–373.
Geudens, I., and Gerhardt, H. (2011). Coordinating cell behaviour during blood
vessel formation. Development 138, 4569–4583.
Granchi, C., and Minutolo, F. (2012). Anticancer agents that counteract tumor
glycolysis. ChemMedChem 7, 1318–1350.
Harjes, U., Bensaad, K., and Harris, A.L. (2012). Endothelial cell metabolism
and implications for cancer therapy. Br. J. Cancer 107, 1207–1212.ell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc. 47
Cell Metabolism
PFKFB3 Blockade Reduces Pathological AngiogenesisHellstro¨m, M., Phng, L.K., Hofmann, J.J., Wallgard, E., Coultas, L., Lindblom,
P., Alva, J., Nilsson, A.K., Karlsson, L., Gaiano, N., et al. (2007). Dll4 signalling
through Notch1 regulates formation of tip cells during angiogenesis. Nature
445, 776–780.
Herrero-Mendez, A., Almeida, A., Ferna´ndez, E., Maestre, C., Moncada, S.,
and Bolan˜os, J.P. (2009). The bioenergetic and antioxidant status of neurons
is controlled by continuous degradation of a key glycolytic enzyme by APC/
C-Cdh1. Nat. Cell Biol. 11, 747–752.
Hindryckx, P., Waeytens, A., Laukens, D., Peeters, H., Van Huysse, J.,
Ferdinande, L., Carmeliet, P., and De Vos, M. (2010). Absence of placental
growth factor blocks dextran sodium sulfate-induced colonic mucosal angio-
genesis, increases mucosal hypoxia and aggravates acute colonic injury. Lab.
Invest. 90, 566–576.
Krueger, J., Liu, D., Scholz, K., Zimmer, A., Shi, Y., Klein, C., Siekmann, A.,
Schulte-Merker, S., Cudmore, M., Ahmed, A., and le Noble, F. (2011). Flt1
acts as a negative regulator of tip cell formation and branchingmorphogenesis
in the zebrafish embryo. Development 138, 2111–2120.
Lalwani, G.A., Rosenfeld, P.J., Fung, A.E., Dubovy, S.R., Michels, S., Feuer,
W., Davis, J.L., Flynn, H.W., Jr., and Esquiabro, M. (2009). A variable-dosing
regimen with intravitreal ranibizumab for neovascular age-related macular
degeneration: year 2 of the PrONTO Study. Am. J. Ophthalmol. 148, 43–58, e1.
Leopold, J.A., Walker, J., Scribner, A.W., Voetsch, B., Zhang, Y.Y., Loscalzo,
A.J., Stanton, R.C., and Loscalzo, J. (2003). Glucose-6-phosphate dehydroge-
nase modulates vascular endothelial growth factor-mediated angiogenesis.
J. Biol. Chem. 278, 32100–32106.
Locasale, J.W., and Cantley, L.C. (2010). Altered metabolism in cancer. BMC
Biol. 8, 88.
Lunt, S.Y., and Vander Heiden, M.G. (2011). Aerobic glycolysis: meeting the
metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27,
441–464.
Miller, J.W., Le Couter, J., Strauss, E.C., and Ferrara, N. (2013). Vascular endo-
thelial growth factor a in intraocular vascular disease. Ophthalmology 120,
106–114.
Niranjan, H.S., Benakappa, N., Reddy, K.B., Nanda, S., and Kamath, M.V.
(2012). Retinopathy of prematurity promising newer modalities of treatment.
Indian Pediatr. 49, 139–143.
Potente, M., Gerhardt, H., and Carmeliet, P. (2011). Basic and therapeutic as-
pects of angiogenesis. Cell 146, 873–887.48 Cell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc.Raez, L.E., Papadopoulos, K., Ricart, A.D., Chiorean, E.G., Dipaola, R.S.,
Stein, M.N., Rocha Lima, C.M., Schlesselman, J.J., Tolba, K., Langmuir,
V.K., et al. (2013). A phase I dose-escalation trial of 2-deoxy-D-glucose alone
or combined with docetaxel in patients with advanced solid tumors. Cancer
Chemother. Pharmacol. 71, 523–530.
Rofagha, S., Bhisitkul, R.B., Boyer, D.S., Sadda, S.R., and Zhang, K.; SEVEN-
UP Study Group (2013). Seven-Year Outcomes in Ranibizumab-Treated
Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study
(SEVEN-UP). Ophthalmology 120, 2292–2299.
Sacharidou, A., Stratman, A.N., andDavis, G.E. (2012). Molecularmechanisms
controlling vascular lumen formation in three-dimensional extracellular
matrices. Cells Tissues Organs (Print) 195, 122–143.
Scott, A., and Fruttiger, M. (2010). Oxygen-induced retinopathy: a model for
vascular pathology in the retina. Eye (Lond.) 24, 416–421.
Seo, M., Kim, J.D., Neau, D., Sehgal, I., and Lee, Y.H. (2011). Structure-based
development of small molecule PFKFB3 inhibitors: a framework for potential
cancer therapeutic agents targeting the Warburg effect. PLoS ONE 6, e24179.
Singh, M., and Ferrara, N. (2012). Modeling and predicting clinical efficacy for
drugs targeting the tumor milieu. Nat. Biotechnol. 30, 648–657.
Stewart, M.W. (2012). The expanding role of vascular endothelial growth factor
inhibitors in ophthalmology. Mayo Clin. Proc. 87, 77–88.
Telang, S., Clem, B.F., Klarer, A.C., Clem, A.L., Trent, J.O., Bucala, R., and
Chesney, J. (2012). Small molecule inhibition of 6-phosphofructo-2-kinase
suppresses t cell activation. J. Transl. Med. 10, 95.
Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A.,
Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010).
Further pharmacological and genetic evidence for the efficacy of PlGF inhibi-
tion in cancer and eye disease. Cell 141, 178–190.
Van Schaftingen, E., Lederer, B., Bartrons, R., and Hers, H.G. (1982). A kinetic
study of pyrophosphate: fructose-6-phosphate phosphotransferase from po-
tato tubers. Application to a microassay of fructose 2,6-bisphosphate. Eur. J.
Biochem. 129, 191–195.
Wynn, T.A., Chawla, A., and Pollard, J.W. (2013). Macrophage biology in
development, homeostasis and disease. Nature 496, 445–455.
Yalcin, A., Telang, S., Clem, B., and Chesney, J. (2009). Regulation of glucose
metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in
cancer. Exp. Mol. Pathol. 86, 174–179.
